Skip to content

MBI for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease

Mindfulness-based Intervention for Pain and Sleep in Adolescents and Young Adults With Sickle Cell Disease: Randomized Clinical Trial

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07797582
Acronym
REMedy_RCT
Enrollment
48
Registered
2026-09-01
Start date
2027-02-01
Completion date
2029-05-01
Last updated
2026-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Sickle Cell Disease, Sleep

Keywords

sleep, mindfulness-based intervention, mobile health, pilot study, pain management

Brief summary

This study examines the efficacy of a mindfulness-based intervention designed to support pain and sleep management in adolescents and young adults with sickle cell disease. Participants will be assigned to either an intervention or usual care group. Participants who are assigned to the intervention group will use a smartphone-based mindfulness program that includes structured modules and guided mindfulness exercises over an approximately 8-week period.

Interventions

BEHAVIORALMindfulness-based intervention

Mobile mindfulness-based intervention for pain and sleep in adolescents and young adults with sickle cell disease

Sponsors

University of Illinois at Chicago
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 39 Years
Healthy volunteers
No

Inclusion criteria

* Individuals aged 15-39 years * Have been diagnosed with SCD * Are able to speak and understand English * Are able to complete questionnaires with minimal or no assistance from a caregiver * Report pain and/or sleep problems as assessed by the Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) short forms * Have access to the internet on a smartphone, tablet, or computer

Exclusion criteria

* Individuals who have significant cognitive limitations that will impair their ability to use and understand the MBI, as per their health care provider or caregiver * Are currently receiving an MBI or have received more than 4 sessions of any MBI in the 6 months prior to the screening

Design outcomes

Primary

MeasureTime frameDescription
Pain interferenceAt 8 weeksPain interference will be measured using Brief Pain Inventory (higher scores indicating greater pain-related interference).

Secondary

MeasureTime frameDescription
Sleep disturbanceAt 8 weeksSleep disturbance will be assessed using the PROMIS Sleep Disturbance Short Form 6a. Items are scored on a T-score metric (mean 50, SD 10), with higher scores indicating greater sleep disturbance.
FatigueAt 8 weeksFatigue will be assessed using the PROMIS Fatigue Short Form 7a, a 7-item patient-reported measure of the experience and impact of fatigue. Items are scored on a T-score metric (mean 50, SD 10), with higher scores indicating greater fatigue.
AnxietyAt 8 weeksAnxiety symptoms will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report measure of anxiety symptom severity over the past 2 weeks (higher scores indicating greater anxiety severity).
DepressionAt 8 weeksDepression will be assessed using the Patient Health Questionnaire-9 (PHQ-9), a 9-item self-report measure of depressive symptom severity over the past 2 weeks (higher scores indicating greater depression severity).
IntentionAt 8 weeksBehavioral intention to engage in mindfulness practice will be assessed using items adapted from the Theory of Planned Behavior (TPB) framework, measuring participants' intention to perform the target behavior (e.g., regular mindfulness practice). Items are rated on a Likert-type scale, with higher scores indicating stronger intention.
Dose intensityAt 8 weeksDose intensity for the intervention group will be quantified using REMedy app usage data, including: (1) total number of modules completed (out of 8), and (2) which specific modules were completed. Higher values indicate greater intervention engagement/dose.
Pain intensityAt 8 weeksPain intensity will be measured using Brief Pain Inventory (higher scores indicating greater pain-related intensity).
Pain catastrophizingAt 8 weeksPain catastrophizing will be assessed using the Concerns About Pain (CAP) Scale, which measures catastrophic thinking about pain (higher scores indicating greater pain catastrophizing).
Physical functionAt 8 weeksPhysical function will be assessed using the PROMIS Physical Function Short Form 6b, a 6-item patient-reported measure of self-reported capability for physical activities. Items are scored on a T-score metric (mean 50, SD 10), with higher scores indicating better physical function.

Contacts

CONTACTDahee Wi, PhD, RN
dwi3@uic.edu312-996-4473
PRINCIPAL_INVESTIGATORDahee Wi, PhD, RN

University of Illinois at Chicago

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 2, 2026